XPH:NYE-SPDR® S&P Pharmaceuticals ETF (USD)

ETF | Health |

Last Closing

USD 41.179

Change

+0.04 (+0.09)%

Market Cap

N/A

Volume

0.01M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-06-05 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
XLV Health Care Select Sector SPDR..

-0.18 (-0.14%)

USD 33.98B
FHLC Fidelity® MSCI Health Care In..

-0.05 (-0.08%)

USD 2.37B
FXH First Trust Health Care AlphaD..

-0.08 (-0.08%)

USD 0.90B
XHE SPDR® S&P Health Care Equipme..

+0.43 (+0.53%)

USD 0.17B
IDNA iShares Genomics Immunology an..

-0.11 (-0.53%)

USD 0.10B
XHS SPDR® S&P Health Care Service..

-0.06 (-0.06%)

USD 0.09B
SBIO ALPS Medical Breakthroughs ETF

+0.09 (+0.29%)

USD 0.08B
HTEC Robo Global® Healthcare Techn..

-0.12 (-0.44%)

USD 0.04B
BBP Virtus LifeSci Biotech Product..

+0.20 (+0.34%)

USD 0.02B
BBC Virtus LifeSci Biotech Clinica..

+0.18 (+0.91%)

USD 0.01B

ETFs Containing XPH

INAV 10.31 % 0.00 %

N/A

N/A
MSSS Northern Lights Fund Trus.. 9.52 % 0.00 %

-0.10 (-0.34%)

USD 0.09B

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -4.21% 35% F 32% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -4.21% 35% F 30% F
Trailing 12 Months  
Capital Gain 1.40% 86% B+ 51% F
Dividend Return 1.25% 94% A 26% F
Total Return 2.65% 86% B+ 43% F
Trailing 5 Years  
Capital Gain -4.81% 33% F 35% F
Dividend Return 5.77% 68% D+ 13% F
Total Return 0.96% 38% F 23% F
Average Annual (5 Year Horizon)  
Capital Gain -4.04% 33% F 19% F
Dividend Return -3.21% 33% F 13% F
Total Return 0.83% 68% D+ 19% F
Risk Return Profile  
Volatility (Standard Deviation) 12.78% 67% D+ 69% C-
Risk Adjusted Return -25.09% 24% F 11% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.